Publication:
Stem cell markers: A guide to neoadjuvant therapy in breast carcinomas

Simple item page
dc.contributor.authorGücin, Zühal
dc.contributor.authorBüyükpınarbaşılı, Nur
dc.contributor.authorGeçer, Melin
dc.contributor.authorErsoy, Yeliz Emine
dc.contributor.authorTürk, Hacı Mehmet
dc.contributor.authorYıldız, Şeyma
dc.contributor.authorAksoy, Direnç Özlem
dc.contributor.institutionauthorGÜCİN, ZÜHAL
dc.contributor.institutionauthorGEÇER, MELİN
dc.contributor.institutionauthorERSOY, YELIZ EMINE
dc.contributor.institutionauthorTÜRK, HACI MEHMET
dc.contributor.institutionauthorYILDIZ, ŞEYMA
dc.date.accessioned2022-06-17T20:59:07Z
dc.date.available2022-06-17T20:59:07Z
dc.date.issued2022-06-01T00:00:00Z
dc.description.abstractBACKGROUND: In recent years, stem cells have been defined as the main cell population responsible for resistance to anticancer therapies. AIM: This study aims to investigate potential associations between the stem cell population and the degree of tumor regression in breast carcinomas treated with neoadjuvant therapy. SETTINGS AND DESIGN: The study included 92 patients with breast carcinoma who received neoadjuvant therapy. Tumor regression was defined based on Miller and Payne grading system. Patients with grade 1 or 2 regression on a 5‑point scale were included in group 1 (n = 37), grade 3 regression in group 2 (n = 32), and grade 4 or 5 regression in group 3 (n = 23). MATERIALS AND METHODS: Immunohistochemical staining was performed on paraffin block sections of every case using CD44, CD24, CD29, CD133, ID4, and ALDH1 antibodies to detect stem cells. STATISTICAL ANALYSIS USED: IBM Statistical Package for the Social Sciences (SPSS), version 23.0 (IBM Corp., Armonk, NY, USA) software was used for statistical analyses, and a P value less than 0.05 was considered statistically significant. RESULTS: Histologically high‑grade tumors are more common in the near‑complete/complete response group (P = 0.004). HER2‑positive tumors were more common in the complete/ near‑complete response group (P = 0.054). Tumor cells positive for stem cell markers CD44 and CD24 were more common in the poor response group (P = 0.027 and P = 0.001, respectively). CD29 expression was reduced in the posttreatment residual tumor tissue in the near‑complete/complete response group. CONCLUSION: High CD44 and CD24 expression may be a predictor of poor response/nonresponse to neoadjuvant therapy in breast carcinomas. KEY WORDS: Breast Cancers, neoadjuvant treatment, stem cell markers, stem cells, tumor regression grade
dc.identifier.citationGücin Z., Büyükpınarbaşılı N., Geçer M., Ersoy Y. E. , Türk H. M. , Yıldız Ş., Aksoy D. Ö. , - Stem cell markers: A guide to neoadjuvant therapy in breast carcinomas-, INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2022
dc.identifier.doi10.4103/ijpm.ijpm_1274_21
dc.identifier.urihttp://hdl.handle.net/20.500.12645/30756
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleStem cell markers: A guide to neoadjuvant therapy in breast carcinomas
dc.typeArticle
dspace.entity.typePublication
local.avesis.idb2651fd9-20de-41d9-aebc-05ebb6de6d2d
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
local.publication.isinternational1
relation.isAuthorOfPublication874eeba5-cd5f-4437-9bdc-55caae8104f2
relation.isAuthorOfPublicationea47803c-bf90-40b3-9ef5-38f85ee5cf80
relation.isAuthorOfPublication29a098c6-acc4-4e05-af39-eeffbc7be778
relation.isAuthorOfPublication1b3a1540-7e57-405d-8a9d-f926d17dcc29
relation.isAuthorOfPublicatione20137ce-7b01-4bcb-9db8-b04458258655
relation.isAuthorOfPublication.latestForDiscovery874eeba5-cd5f-4437-9bdc-55caae8104f2
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c
Files
Collections
Yayınlar - Eserler